Part of UCB PHARMA SA
Belgian multinational biopharmaceutical company headquartered in Brussels, focused on research and development of medications for epilepsy, Parkinson's disease, Crohn's disease, and other conditions.
Clinical Trials
270
0 active
Approvals
137
Total approvals
Agencies
5
Regulatory bodies
Founded
1928
Completed
247
91.5%
Terminated
17
6.3%
Withdrawn
6
2.2%
- ReAlta Life Sciences appointed Jonathan Rigby, a seasoned biotech executive with a track record of raising over $150 million and leading companies through IPOs and strategic exits, to its Board of Directors. - Rigby brings extensive experience from leadership roles at companies including Zogenix (acquired by UCB Pharma for $2 billion) and SteadyMed Therapeutics (acquired by United Therapeutics for $350 million). - The appointment comes as ReAlta advances pegtarazimod, a dual-mechanism peptide targeting neutrophil-driven inflammation and complement activation for treating conditions like Hypoxic Ischemic Encephalopathy in newborns. - Pegtarazimod has received multiple FDA and EMA designations including Orphan Drug and Fast Track status for Hypoxic Ischemic Encephalopathy and acute Graft vs Host Disease.
- A new comprehensive report analyzes the global clinical trials landscape for Lennox-Gastaut Syndrome, providing critical data on trial numbers, enrollment figures, and regional distribution across G7 and E7 nations. - The analysis covers diverse aspects of clinical trials categorized by region, trial phase, status, sponsorship type, and endpoint analysis, highlighting prominent drugs currently under investigation. - Major pharmaceutical companies including Jazz Pharmaceuticals, Takeda, UCB, GSK, and Eisai are actively conducting trials in this rare epilepsy syndrome space. - The report aims to facilitate strategic business planning and investment decisions while identifying optimal locations for conducting efficient clinical trials in this challenging therapeutic area.
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
- The injectable drug delivery market is projected to reach $1,139.4 billion by 2029, driven by complex biologics and increased demand for patient self-administration. - Industry leaders from Pfizer, GSK, Sandoz, and other major pharmaceutical companies will gather at the Injectable Drug Delivery Conference in London on June 24-25, 2025. - The conference agenda focuses on critical challenges including subcutaneous delivery of biologics, large-volume injectables, and sustainable device development. - A separate PODD 2025 conference in Boston will feature pharmaceutical innovation leaders discussing strategic partnerships and drug delivery technology evaluation frameworks.
- The myasthenia gravis market across seven major markets is projected to grow from $6.1 billion in 2024 to $10.3 billion by 2034, representing a 5.3% compound annual growth rate. - Seven late-stage pipeline products including CRD-1, Descartes-08, Imaavy, gefurulimab, inebilizumab, pozelimab + cemdisiran combination therapy, and telitacicept are expected to drive market expansion. - The combination therapy of pozelimab and cemdisiran shows particular promise for treating seronegative myasthenia gravis patients, addressing a significant unmet medical need. - Despite growth potential, generic erosion and biosimilar competition pose barriers, particularly affecting high-grossing disease-modifying therapies that generated an estimated $5 billion in combined sales in 2024.
- The NHS has approved fenfluramine, the first non-cannabis based treatment for Lennox-Gastaut syndrome (LGS), offering new hope for children aged 2 and above with this severe form of epilepsy. - Clinical trials demonstrated that fenfluramine reduces drop seizure frequency by 26.5% on average, with over 25% of patients experiencing a 50% or greater reduction in seizures. - The treatment will be fast-tracked through NHS England's Innovative Medicines Fund, making it available three months earlier for eligible patients who cannot tolerate existing cannabis-based treatments.
- UCB Pharma aims to expand its portfolio in South Korea after securing approvals for Bimzelx (bimekizumab) for plaque psoriasis and Zilbrysq (zilucoplan) for myasthenia gravis. - Fintepla (fenfluramine) is under review for Dravet syndrome and Lennox-Gastaut syndrome, potentially receiving expedited approval via the GIFT program. - Rystiggo (rozanolixizumab), a monoclonal antibody for myasthenia gravis, may also see accelerated approval if designated under Korea’s GIFT program. - Bimzelx is poised to compete in the plaque psoriasis market, showing superior efficacy in trials against Humira, Stelara, and Cosentyx.
- The FDA has approved bimekizumab (Bimzelx; UCB Pharma) for treating moderate to severe hidradenitis suppurativa in adults, marking its fifth approved indication in the US. - Approval was based on the BE HEARD I and BE HEARD II trials, which demonstrated significant clinical response at week 16 that was sustained through week 48. - Bimekizumab, a monoclonal antibody inhibiting IL-17A and IL-17F, showed greater improvement compared to placebo in reducing abscesses and inflammatory nodules. - The studies' primary endpoint, HiSCR50, was achieved by patients on bimekizumab, offering a new treatment option for this chronic inflammatory skin disorder.
- The FDA has approved bimekizumab-bkzx (Bimzelx) for treating moderate-to-severe hidradenitis suppurativa (HS) in adult patients, addressing a significant unmet clinical need. - Bimekizumab, a humanized IgG1 monoclonal antibody, uniquely targets and inhibits both interleukin (IL)-17A and IL-17F cytokines, providing a more complete blockade of inflammation. - Clinical trials BE HEARD I and BE HEARD II demonstrated that bimekizumab significantly reduced HS symptoms, with many patients achieving a 75% reduction in inflammatory lesions. - Long-term data from an open-label extension study showed continued improvement, with approximately 40% of patients achieving complete clearance of abscesses and inflammatory nodules.
• Bepranemab, a monoclonal antibody from UCB Pharma, is the first to demonstrate a slowing of tau tangle accumulation in Alzheimer's patients, marking a potential shift in treatment strategies. • Phase 2 trial data suggests cognitive benefits in a subgroup with low baseline tau levels and without the ApoE4 mutation, indicating a targeted approach may be necessary for efficacy. • The trial results support the hypothesis that extracellular tau 'seeds' drive Alzheimer's progression, opening avenues for understanding disease mechanisms and developing combination therapies. • Several companies are developing antibodies targeting the microtubule binding region (MTBR) of tau, with ongoing trials exploring their impact on tau spread and clinical outcomes.
